You are here: Controversies / Shridhar Sharma: Insulin coma treatment: Facts and controversies / Donald F. Klein’s comment on Shridhar Sharma’s reply to Vimal K. Razdan’s comment
Thursday, 23.03.2017

Shridhar Sharma: Insulin coma treatment: Facts and controversies

Donald F. Klein’s comment on Shridhar Sharma’s reply to Vimal K. Razdan’s comment

 

            Dr Sharma agrees that all clinical comparative trials of ICT have been negative. Yet he holds out hope that further research is warranted because of open observations and assorted preclinical findings. Dr Razdan agrees.

To be persuasive, evidence should be cited that these preclinical findings have led to the development of relevant compounds for the treatment of schizophrenia. I believe such findings have the same dismal clinical track record as ICT.

            In general, useful clinical developments in psychiatry, starting from preclinical findings, are scarce to absent; yet they are regularly cited as substantive rather than speculative.

Donald Klein

September 29, 2016